Pancreatic Cancer: Leading to Failure of Rivaroxaban as an Anticoagulant
vascular thromboembolism, VTE, novel oral anticoagulants, hypercoagulability, patient mortality, pancreatic cancer, medicine efficacy
Digestive System Diseases | Gastroenterology | Internal Medicine | Medicine and Health Sciences
Vascular Thromboembolism (VTE) is seen with hypercoagulable state and it can be a reason of significant morbidity and mortality. Cancer is considered as one of the most common causes of hypercoagulability and developing VTE. Since novel oral anticoagulants (NOAC) have been introduced in market for VTE prophylaxis and treatment, their use have been increased significantly as they are easy to use without episodic monitoring. Rivaroxaban is one of the commonly used NOACs and some of studies have shown its good efficacy for VTE.
Publisher or Conference
American College of Gastroenterology Annual Scientific Meeting 2019
Pratikkumar Vekaria, MD, Chandrika Raiyani, MD, Daniel Robitshek, MD, Tejas Raiyani, MD. P0998 - Pancreatic Cancer: Leading to Failure of Rivaroxaban as an Anticoagulant. Program No. P0998. ACG 2019 Annual Scientific Meeting Abstracts. San Antonio, Texas: American College of Gastroenterology.